Publications by authors named "Amol D Dhamane"

Claim this Profile
J
Joint modeling of progression-free survival and patient-reported outcomes to evaluate the association between disease progression and symptoms among patients with relapsed/refractory multiple myeloma.
Stefan Knop, Hermann Einsele, Devender Dhanda, Thomas S Marshall, Laurie Eliason, Amol D Dhamane

J Patient Rep Outcomes· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Karthik Ramasamy, Ravi Vij, David Kuter, David Cella, Brian G M Durie, Amol D Dhamane

Clin Lymphoma Myeloma Leuk· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism.
Alexander T Cohen, Amol D Dhamane, Xuejun Liu, Risho Singh, Stella Han

J Natl Compr Canc Netw· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis.
Marissa B Betts, Xuejun Liu, Daniela R Junqueira, Kyle Fahrbach, Binod Neupane, Amol D Dhamane

Semin Thromb Hemost· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of anticoagulants among patients with venous thromboembolism and common cancers or cancers with high venous thromboembolism risk.
Alexander T Cohen, Virginia Noxon, Amol D Dhamane, Shrushti Shah, Dionne M Hines

Future Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal disease.
Alexander T Cohen, Virginia Noxon, Amol D Dhamane, Shrushti Shah, Dionne M Hines

Curr Med Res Opin· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation.
Xuemei Luo, Jose Chaves, Amol D Dhamane, Feng Dai, Dominick Latremouille-Viau

Am Heart J Plus· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Payer formulary tier increases of apixaban: how patients respond and potential implications.
Steven Deitelzweig, Emi Terasawa, Nipun Atreja, Amiee Kang, Dionne M Hines, Amol D Dhamane

Curr Med Res Opin· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.
Alexander T Cohen, Janvi Sah, Amol D Dhamane, Dionne M Hines, Theodore Lee

Adv Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer.
Amol D Dhamane, Shrushti Shah, Virginia Noxon, Robert Bruette, Mauricio Ferri

Thromb Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Amol D Dhamane, Mauricio Ferri, Allison Keshishian, Cristina Russ, Nipun Atreja

Adv Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19.
Steven Deitelzweig, Julia Zhu, Jenny Jiang, Xuemei Luo, Allison Keshishian, Amol D Dhamane

Curr Med Res Opin· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.
Alexander T Cohen, Janvi Sah, Amol D Dhamane, Theodore Lee, Lisa Rosenblatt

PLoS One· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
Gregory Y H Lip, Richard R Murphy, Farhad Sahiar, Timothy J Ingall, Amol D Dhamane

JAMA Netw Open· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
Alexander T Cohen, Janvi Sah, Amol D Dhamane, Theodore Lee, Lisa Rosenblatt

Thromb Haemost· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA.
Amol D Dhamane, Inmaculada Hernandez, Manuela Di Fusco, Cynthia Gutierrez, Mauricio Ferri

Am J Cardiovasc Drugs· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs.
Steve Deitelzweig, Janvi Sah, Amiee Kang, Cristina Russ, Madison Preib, Amol D Dhamane

Am J Cardiol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
Alexander T Cohen, Janvi Sah, Amol D Dhamane, Theodore Lee, Lisa Rosenblatt

Adv Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy.
Gregory Y H Lip, Allison Keshishian, Amiee Kang, Amol D Dhamane, Xuemei Luo

Eur Heart J Cardiovasc Pharmacother· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer.
Steven Deitelzweig, Allison V Keshishian, Yan Zhang, Amiee Kang, Amol D Dhamane

JACC CardioOncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
Gregory Y H Lip, Allison V Keshishian, Yan Zhang, Amiee Kang, Amol D Dhamane

JAMA Netw Open· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity.
Steven Deitelzweig, Allison Keshishian, Amiee Kang, Amol D Dhamane, Xuemei Luo

Adv Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients.
Steven Deitelzweig, Allison Keshishian, Amiee Kang, Amol D Dhamane, Xuemei Luo

Therap Adv Gastroenterol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA.
Steven Deitelzweig, Amol D Dhamane, Manuela Di Fusco, Cristina Russ, Lisa Rosenblatt

J Med Econ· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States.
Steven Deitelzweig, Christine L Baker, Amol D Dhamane, Jack Mardekian, Oluwaseyi Dina

J Drug Assess· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis